Use of tuberculosis interferon-gamma release assays (IGRAs) in low- and middle-income countries : policy statement

loading…

Catalogue record: Dublin Core XML — 10665-44759.dc.xml the item's metadata record · KG node — item-10665-44759.json the item's catalogue node, on GitHub · hdl:10665/44759 the item upstream

Summary

This policy statement provides evidence-based recommendations on the use of commercial interferon-gamma release assays (IGRAs) for tuberculosis (TB) in low- and middle-income countries, particularly settings with a high TB and/or HIV burden. Based on systematic reviews and GRADE assessment, it evaluates IGRAs for diagnosis of active TB, detection of latent TB infection (LTBI) in children and people living with HIV, screening of health care workers and contacts, outbreak investigations, and prediction of progression to active disease. The evidence was generally of low or very low quality and did not demonstrate superior performance of IGRAs over the tuberculin skin test (TST). WHO recommends that IGRAs and the TST not be used to diagnose active TB or identify individuals at risk of developing active disease, and that IGRAs not replace the TST for LTBI diagnosis in children, people living with HIV, or contacts. Given comparable performance, greater cost and technical complexity, replacing the TST with IGRAs as a public health intervention in resource-constrained settings is not recommended.

The abstract from the item's catalogue record, as WHO published it.

10665-44759.pdf is not held on this site. Find it at 9789241502672_eng.pdf at its source.

The whole library

Source JSON-LD and assets

The published files this page is a rendering of.


folio-assistant — code under the Apache License 2.0, documentation under CC BY 3.0. Generated schema and API references are rebuilt from source on every push to main.

deployed dev